Eligibility for Noninvasive Testing Based on the 2021 American Heart Association/American College of Cardiology Guideline for the Evaluation and Diagnosis of Stable Chest Pain: Implications From the PROMISE Trial.
Publication
, Journal Article
Fordyce, CB; Hill, CL; Foldyna, B; Douglas, PS; PROMISE Investigators,
Published in: Circulation
August 16, 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
August 16, 2022
Volume
146
Issue
7
Start / End Page
582 / 584
Location
United States
Related Subject Headings
- United States
- Risk Assessment
- Humans
- Eligibility Determination
- Chest Pain
- Cardiovascular System & Hematology
- Cardiovascular System
- Cardiology
- American Heart Association
- 4207 Sports science and exercise
Citation
APA
Chicago
ICMJE
MLA
NLM
Fordyce, C. B., Hill, C. L., Foldyna, B., Douglas, P. S., & PROMISE Investigators, . (2022). Eligibility for Noninvasive Testing Based on the 2021 American Heart Association/American College of Cardiology Guideline for the Evaluation and Diagnosis of Stable Chest Pain: Implications From the PROMISE Trial. Circulation, 146(7), 582–584. https://doi.org/10.1161/CIRCULATIONAHA.122.059024
Fordyce, Christopher B., C Larry Hill, Borek Foldyna, Pamela S. Douglas, and Pamela S. PROMISE Investigators. “Eligibility for Noninvasive Testing Based on the 2021 American Heart Association/American College of Cardiology Guideline for the Evaluation and Diagnosis of Stable Chest Pain: Implications From the PROMISE Trial.” Circulation 146, no. 7 (August 16, 2022): 582–84. https://doi.org/10.1161/CIRCULATIONAHA.122.059024.
Fordyce CB, Hill CL, Foldyna B, Douglas PS, PROMISE Investigators. Eligibility for Noninvasive Testing Based on the 2021 American Heart Association/American College of Cardiology Guideline for the Evaluation and Diagnosis of Stable Chest Pain: Implications From the PROMISE Trial. Circulation. 2022 Aug 16;146(7):582–4.
Fordyce, Christopher B., et al. “Eligibility for Noninvasive Testing Based on the 2021 American Heart Association/American College of Cardiology Guideline for the Evaluation and Diagnosis of Stable Chest Pain: Implications From the PROMISE Trial.” Circulation, vol. 146, no. 7, Aug. 2022, pp. 582–84. Pubmed, doi:10.1161/CIRCULATIONAHA.122.059024.
Fordyce CB, Hill CL, Foldyna B, Douglas PS, PROMISE Investigators. Eligibility for Noninvasive Testing Based on the 2021 American Heart Association/American College of Cardiology Guideline for the Evaluation and Diagnosis of Stable Chest Pain: Implications From the PROMISE Trial. Circulation. 2022 Aug 16;146(7):582–584.
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
August 16, 2022
Volume
146
Issue
7
Start / End Page
582 / 584
Location
United States
Related Subject Headings
- United States
- Risk Assessment
- Humans
- Eligibility Determination
- Chest Pain
- Cardiovascular System & Hematology
- Cardiovascular System
- Cardiology
- American Heart Association
- 4207 Sports science and exercise